Skip to content

Ultrasound Guided Pectoral Nerves Blockade for Persistent Pain After Breast Cancer Surgery

Ultrasound Guided Pectoral Nerves (Pecs) Blockade in Persistent Pain After Breast Cancer Surgery

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02349581
Acronym
PPBCS
Enrollment
6
Registered
2015-01-29
Start date
2014-11-30
Completion date
Unknown
Last updated
2015-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent Pain After Breast Cancer Surgery

Keywords

Anesthetics, Local, Mastectomy, Neuralgia, Nerve block

Brief summary

This is a pilot study of the pectoral nerves block (PECS) in patients with persistent pain after breast cancer surgery.

Detailed description

This study is in 2 parts: Part 1 is a description of the anatomy of the PECS block in pain free, unoperated patients using ultrasonography (non invasive). Part 2 is the administration of the block to patients that have persistent pain after breast cancer surgery. Before and after the block we will take a detailed pain history and do neurophysiological tests called quantitative sensory testing (QST). These tests assess the patients' ability to feel warmth, cold and test their thresholds for pain. The block is then administered using ultrasound guidance and 20mls of 0.25% bupivacaine is injected in the pectoral muscles on the side with pain. Thirty minutes after the block, the pain is re assessed and the QST is repeated.

Interventions

PROCEDUREPECS block

Ultrasound guided delivery of local anesthetic between the pectoral muscles

DRUGBupivacaine

Sponsors

Kehlet, Henrik, M.D., Ph.D.
CollaboratorINDIV
Rigshospitalet, Denmark
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Female patients, aged 18 years or over, treated for breast cancer * Patients with persistent pain in the breast after surgical treatment for breast cancer. Their pain score must be 4 or more on the numerical rating scale (NRS).

Exclusion criteria

* breast surgery within the last 12 months * previous cosmetic surgery * bilateral breast cancer (receiving bilateral intervention) * pregnant or breast feeding * neurological disease * on-going treatment for severe mental illness or who abuse alcohol or drugs * are unable to understand written or spoken Danish or English * lack mental capacity to give informed consent or cooperate with the neurophysiological testing * an allergy to amide local anaesthetics * pacemaker in situ * received treatment outside guidelines and recommendations from the Danish Breast Cancer Co-operative Group (DBCG)

Design outcomes

Primary

MeasureTime frameDescription
Differences in summed pain intensity score (SPI)30 minutes after blockadeSPI is a combination of pain at rest + pain on arm abduction + pain with 100kPa pressure. SPI will be taken before and 30 minutes after the PECS block

Secondary

MeasureTime frameDescription
Differences in quantitative sensory testing (QST) values30 minutes after blockadeQST consists of sensory mapping (delineating areas of hypo/hyperesthesia and/or allodynia), warm detection thresholds, cool detection thresholds, heat pain thresholds, suprathermal heat pain response and pressure pain thresholds. These will be measured before and 30 minutes after the PECS block

Other

MeasureTime frameDescription
Longer term effects (Daily pain scores and functional questionnaire)1 week after blockadePatients will complete a pain diary for 5 consecutive days before administration of the PECS block and 7 consecutive days after the block. The patients also complete a functional questionnaire the day before the block and again exactly one week after the block.

Countries

Denmark

Contacts

Primary ContactNelun Wijayasinghe, MBBS, BSc
nelun.wijayasinghe@regionh.dk+45 35456643
Backup ContactKenneth G Andersen, MD, PhD
kenneth.geving.andersen@rh.regionh.dk+45 35 45 66 43

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026